Bonus BioGroup Ltd. (BBIXF)
USD 0.03
(0.0%)
USD 0.03
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -1.77 Million ILS | 95.73% |
| 2022 | -41.67 Million ILS | 37.9% |
| 2021 | -67.1 Million ILS | -513.82% |
| 2020 | -10.93 Million ILS | -289.43% |
| 2019 | 5.77 Million ILS | 166.79% |
| 2018 | -8.64 Million ILS | -217.1% |
| 2017 | -2.72 Million ILS | -94.5% |
| 2016 | -1.4 Million ILS | 68.24% |
| 2015 | -4.41 Million ILS | -351.95% |
| 2014 | -976 Thousand ILS | -26.1% |
| 2013 | -774 Thousand ILS | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -3.42 Million ILS | 39.68% |
| 2024 Q1 | -5.67 Million ILS | -218.77% |
| 2023 Q4 | -1.77 Million ILS | 84.92% |
| 2023 Q2 | -27.25 Million ILS | 19.41% |
| 2023 Q3 | -11.79 Million ILS | 56.73% |
| 2023 FY | -1.77 Million ILS | 95.73% |
| 2023 Q1 | -33.81 Million ILS | 18.84% |
| 2022 Q1 | -59.82 Million ILS | 10.85% |
| 2022 FY | -41.67 Million ILS | 37.9% |
| 2022 Q4 | -41.67 Million ILS | 14.51% |
| 2022 Q3 | -48.74 Million ILS | 14.07% |
| 2022 Q2 | -56.72 Million ILS | 5.18% |
| 2021 Q3 | -78.69 Million ILS | 2.78% |
| 2021 FY | -67.1 Million ILS | -513.82% |
| 2021 Q2 | -80.94 Million ILS | 3.43% |
| 2021 Q1 | -83.82 Million ILS | -666.74% |
| 2021 Q4 | -67.1 Million ILS | 14.73% |
| 2020 Q4 | -10.93 Million ILS | -476.97% |
| 2020 FY | -10.93 Million ILS | -289.43% |
| 2020 Q3 | 2.9 Million ILS | 113.71% |
| 2020 Q2 | 1.35 Million ILS | 169.31% |
| 2020 Q1 | -1.95 Million ILS | -133.93% |
| 2019 Q4 | 5.77 Million ILS | 100.59% |
| 2019 Q2 | 4.79 Million ILS | 78.82% |
| 2019 Q1 | 2.68 Million ILS | 131.04% |
| 2019 FY | 5.77 Million ILS | 166.79% |
| 2019 Q3 | 2.87 Million ILS | -40.01% |
| 2018 Q2 | -7.43 Million ILS | -86.11% |
| 2018 FY | -8.64 Million ILS | -217.1% |
| 2018 Q4 | -8.64 Million ILS | 9.18% |
| 2018 Q1 | -3.99 Million ILS | -46.61% |
| 2018 Q3 | -9.51 Million ILS | -27.96% |
| 2017 Q1 | -2.24 Million ILS | -60.39% |
| 2017 Q3 | -2.03 Million ILS | 37.57% |
| 2017 Q4 | -2.72 Million ILS | -33.64% |
| 2017 FY | -2.72 Million ILS | -94.5% |
| 2017 Q2 | -3.26 Million ILS | -45.35% |
| 2016 Q2 | -2.24 Million ILS | 38.93% |
| 2016 Q1 | -3.66 Million ILS | 16.84% |
| 2016 FY | -1.4 Million ILS | 68.24% |
| 2016 Q4 | -1.4 Million ILS | 62.09% |
| 2016 Q3 | -3.69 Million ILS | -65.0% |
| 2015 Q2 | -2.89 Million ILS | -58.72% |
| 2015 Q1 | -1.82 Million ILS | -86.89% |
| 2015 FY | -4.41 Million ILS | -351.95% |
| 2015 Q4 | -4.41 Million ILS | -284.23% |
| 2015 Q3 | -1.14 Million ILS | 60.35% |
| 2014 Q4 | -976 Thousand ILS | -56.16% |
| 2014 Q2 | -493 Thousand ILS | -50.3% |
| 2014 Q1 | -328 Thousand ILS | 57.62% |
| 2014 FY | -976 Thousand ILS | -26.1% |
| 2014 Q3 | -625 Thousand ILS | -26.77% |
| 2013 Q3 | -318 Thousand ILS | 33.75% |
| 2013 FY | -774 Thousand ILS | 0.0% |
| 2013 Q2 | -480 Thousand ILS | 12.57% |
| 2013 Q4 | -774 Thousand ILS | -143.4% |
| 2013 Q1 | -549 Thousand ILS | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1310.00 USD | -135701.527% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 71.782% |
| Neon Bloom, Inc. | 622.36 Thousand USD | 385.846% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | -612.683% |
| Qrons Inc. | 351.42 Thousand USD | 606.222% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 380.084% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 104.157% |
| BioStem Technologies, Inc. | 4.47 Million USD | 139.781% |
| Skye Bioscience, Inc. | -5.72 Million USD | 68.906% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | -8617.17% |
| Rebus Holdings, Inc. | 305 Thousand USD | 683.279% |
| CSL Limited | 10.52 Billion USD | 100.017% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 104.096% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 108.774% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | 9054.548% |
| Adynxx, Inc. | - USD | Infinity% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 131.496% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 111.286% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 143.2% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | 542.704% |
| SQZ Biotechnologies Company | -36.23 Million USD | 95.091% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | 179.341% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | 291.871% |
| Mesoblast Limited | 55.85 Million USD | 103.185% |
| Marizyme, Inc. | 18.56 Million USD | 109.58% |
| Genus plc | 190.6 Million USD | 100.933% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | 179.568% |
| Pharming Group N.V. | 109.8 Million USD | 101.62% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | 306.803% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | 246.554% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | 361.618% |
| ContraFect Corporation | -6.02 Million USD | 70.478% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | 1421.311% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | 253.969% |
| IMV Inc. | 7.67 Million USD | 123.193% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 132.334% |
| MultiCell Technologies, Inc. | 90.04 USD | 1975888.538% |
| ONE Bio Corp. | 9.04 Million USD | 119.679% |
| Accustem Sciences Inc. | -733.97 Thousand USD | -142.378% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 113.742% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | 1.36 Million USD | 230.047% |
| Q BioMed Inc. | 4.06 Million USD | 143.818% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 105.822% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | 276.538% |
| Biomind Labs Inc. | 711.4 Thousand USD | 350.07% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 102.938% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | 188.977% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 113.891% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | 594.565% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | 1372.496% |
| Curative Biotechnology, Inc. | 2.2 Million USD | 180.791% |
| GB Sciences, Inc. | 1.74 Million USD | 201.813% |
| Alpha Cognition Inc. | -183.78 Thousand USD | -867.963% |
| HST Global, Inc. | 96.79 Thousand USD | 1937.943% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | 962.683% |
| Halberd Corporation | 144.72 Thousand USD | 1329.262% |
| Enzolytics Inc. | 981.65 Thousand USD | 281.224% |
| Agentix Corp. | 37.63 Thousand USD | 4827.485% |
| Resverlogix Corp. | 6.45 Million USD | 127.577% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | -164.304% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -2.02 Billion USD | 99.912% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 96.216% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 125.159% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 165.679% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 79.875% |
| AVAX Technologies, Inc. | -5.9 Million USD | 69.864% |
| Zenith Capital Corp. | 10.06 Thousand USD | 17776.868% |
| Genscript Biotech Corporation | -1.06 Billion USD | 99.832% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | 987.583% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | 174.559% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | 1181.4% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | -9611.759% |
| Kadimastem Ltd | -253.1 Thousand USD | -602.879% |
| Helix BioMedix, Inc. | -2.57 Million USD | 30.779% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | 983.958% |
| LadRx Corporation | -2.03 Million USD | 12.643% |
| Cell Source, Inc. | 9.23 Million USD | 119.27% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 380.084% |
| NovAccess Global Inc. | 2.17 Million USD | 181.663% |
| Affymax, Inc. | -5.59 Million USD | 68.215% |
| Itoco Inc. | 228.3 Thousand USD | 879.221% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | 1408.194% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 135.889% |
| Mobile Lads Corp. | 484.23 Thousand USD | 467.386% |
| CytoDyn Inc. | 20.26 Million USD | 108.78% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | -274861.36% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | -19094.376% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 123.086% |
| SYBLEU INC | 473.71 Thousand USD | 475.543% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 139.915% |
| International Stem Cell Corporation | 2.59 Million USD | 168.687% |
| Bioxytran, Inc. | 1.89 Million USD | 193.685% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | 2950.368% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 181.572% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | 3.43 Million USD | 151.805% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 120.8% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | 772.6 Thousand USD | 330.259% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | -42.32% |
| Neutra Corp. | 52.18 Thousand USD | 3508.895% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | 28.526% |
| PureTech Health plc | -167.19 Million USD | 98.936% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | -626.395% |
| IXICO plc | -4.44 Million USD | 59.974% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 113.458% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 103.243% |
| CSL Limited | 10.52 Billion USD | 100.017% |
| Cellectis S.A. | -43.81 Million USD | 95.94% |